Generalizing Amgen: Fool by Numbers

On Jan. 25, biotechnology company Amgen (NYSE: AMGN  ) released fourth-quarter earnings for the period ended Dec. 31, 2006.

• Net revenues rose 17.2%, driven by the strong worldwide performance of the company's pharmaceutical products, especially Aranesp and Enbrel.
• The company expects to file for approval of AMG 531 in 2007.
• In the fourth quarter, Amgen repurchased 3.3 million shares at a total cost of $245 million, with full-year repurchases totaling 70.2 million shares at a total cost of $5 billion. In December, the company's board approved a new $5 billion share repurchase plan.
• The company expects the total revenues for 2007 to be in the range of $15.4 billion to $16 billion and adjusted EPS to be in the range of $4.30 to $4.50.
• Amgen is a four-star stock in Motley Fool CAPS.

(Figures in millions, except per-share data)

Income Statement Highlights

	Q4 2006	Q4 2005	Change
Sales	$3,835	$3,271	17.2%
Net Profit	$833	$824	1.1%
EPS	$0.71	$0.66	7.6%
Diluted Shares	1,180	1,243	(5.1%)

Get back to basics with a look at the income statement.

Margin Checkup

	Q4 2006	Q4 2005	Change*
Gross Margin	85.4%	84.4%	1.0
Operating Margin	25.8%	33.7%	(7.9)
Net Margin	21.7%	25.2%	(3.5)

*Expressed in percentage points.

Margins are the earnings engine. See how they work.

Balance Sheet Highlights

Assets	Q4 2006	Q4 2005	Change
Cash + ST Invest.	$6,277	$5,255	19.4%
Accounts Rec.	$2,124	$1,769	20.1%
Inventory	$1,903	$1,258	51.3%

Liabilities	Q4 2006	Q4 2005	Change
Accounts Payable	$5,144	$3,595	43.1%
Long-Term Debt	$7,134	$3,957	80.3%

Learn the ways of the balance sheet.

Cash Flow Highlights
Amgen didn't provide cash-flow data. Boo!

Find out why Fools always follow the money.

Related Companies:

• Genentech (NYSE: DNA  )
• Gilead Sciences (Nasdaq: GILD  )
• Celgene (Nasdaq: CELG  )
• Genzyme (Nasdaq: GENZ  )
• Biogen Idec (Nasdaq: BIIB  )

Related Foolishness:

• Amgen's Ho-Hum Quarter
• Neanderthal DNA Enlightens Investors
• Genentech Gets Another Approval

Biogen Idec is a Motley Fool Stock Advisor recommendation. To find out why, you can take a 30-day free trial of the newsletter.

Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.